NASDAQ:CVRX CVRx (CVRX) Stock Price, News & Analysis $7.57 -0.28 (-3.57%) (As of 02:52 PM ET) Add Compare Share Share Today's Range$7.52▼$8.0550-Day Range$7.15▼$12.2052-Week Range$6.40▼$33.13Volume101,647 shsAverage Volume264,601 shsMarket Capitalization$163.48 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get CVRx alerts: Email Address CVRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside76.6% Upside$13.67 Price TargetShort InterestBearish19.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 11 Articles This WeekInsider TradingAcquiring Shares$322,545 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.56) to ($2.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.50 out of 5 starsMedical Sector279th out of 927 stocksSurgical & Medical Instruments Industry36th out of 101 stocks 4.4 Analyst's Opinion Consensus RatingCVRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCVRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CVRx's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted19.05% of the float of CVRx has been sold short.Short Interest Ratio / Days to CoverCVRx has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in CVRx has recently decreased by 1.29%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCVRx does not currently pay a dividend.Dividend GrowthCVRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CVRX. Previous Next 2.1 News and Social Media Coverage News SentimentCVRx has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for CVRx this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CVRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CVRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $322,545.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders18.90% of the stock of CVRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.27% of the stock of CVRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CVRx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CVRx are expected to grow in the coming year, from ($2.56) to ($2.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CVRx is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CVRx is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCVRx has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CVRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About CVRx Stock (NASDAQ:CVRX)CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More CVRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVRX Stock News HeadlinesAugust 16, 2024 | insidertrades.comCVRx, Inc. (NASDAQ:CVRX) Director Joseph P. Slattery Acquires 3,000 SharesSeptember 14 at 1:39 AM | americanbankingnews.comCVRx, Inc. Expected to Earn FY2024 Earnings of ($2.54) Per Share (NASDAQ:CVRX)September 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.September 12, 2024 | finance.yahoo.comCVRx touts positive two-year data for heart failure neuromodulation deviceSeptember 12, 2024 | msn.comCantor Fitzgerald Initiates Coverage of CVRx (CVRX) with Overweight RecommendationSeptember 11, 2024 | americanbankingnews.comCVRx (NASDAQ:CVRX) Earns Overweight Rating from Analysts at Cantor FitzgeraldSeptember 8, 2024 | markets.businessinsider.comAziyo Biologics (ELUT) Receives a Buy from Lake StreetSeptember 6, 2024 | americanbankingnews.comBrokerages Set CVRx, Inc. (NASDAQ:CVRX) Price Target at $13.60September 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.September 3, 2024 | globenewswire.comCVRx Announces Appointment of Two New Board MembersAugust 24, 2024 | uk.finance.yahoo.comIntegra Lifesciences Holdings Corp (IL3.DU)August 21, 2024 | markets.businessinsider.comLake Street Remains a Buy on CVRx (CVRX)August 19, 2024 | globenewswire.comCVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAugust 17, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXAugust 13, 2024 | globenewswire.comCVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAugust 9, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXAugust 8, 2024 | globenewswire.comCVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx, Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the FirmAugust 8, 2024 | finance.yahoo.comInsider Buying: CVRx President Bought US$251k Of SharesSee More Headlines Receive CVRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CVRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/29/2024Today9/16/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:CVRX CUSIPN/A CIK1235912 Webwww.cvrx.com Phone763-416-2840Fax763-416-2841Employees160Year FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$15.00 Low Stock Price Target$12.00 Potential Upside/Downside+80.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,200,000.00 Net Margins-122.52% Pretax Margin-122.16% Return on Equity-77.62% Return on Assets-51.34% Debt Debt-to-Equity Ratio0.53 Current Ratio10.08 Quick Ratio8.85 Sales & Book Value Annual Sales$44.39 million Price / Sales3.68 Cash FlowN/A Price / Cash FlowN/A Book Value$3.65 per share Price / Book2.07Miscellaneous Outstanding Shares21,596,000Free Float17,514,000Market Cap$163.48 million OptionableOptionable Beta1.27 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Kevin Hykes (Age 58)President, CEO & Director Mr. Jared Oasheim (Age 40)Chief Financial Officer Comp: $446.1kMr. Paul Verrastro (Age 61)Chief Marketing & Strategy Officer Comp: $529.84kMr. Paul PignatoVice President of OperationsMs. Jonelle R. Burnham (Age 53)Vice President & General Counsel Mr. Craig Palmer (Age 47)Senior Vice President of US Sales More ExecutivesKey CompetitorsTELA BioNASDAQ:TELABeyond AirNASDAQ:XAIRPAVmedNASDAQ:PAVMLiquidiaNASDAQ:LQDASI-BONENASDAQ:SIBNView All CompetitorsInsiders & InstitutionsJoseph P SlatteryBought 3,000 shares on 8/15/2024Total: $24,300.00 ($8.10/share)Squarepoint Ops LLCBought 19,165 shares on 8/14/2024Ownership: 0.426%Marshall Wace LLPBought 41,265 shares on 8/14/2024Ownership: 0.191%Dimensional Fund Advisors LPBought 18,245 shares on 8/9/2024Ownership: 0.084%Joseph P SlatteryBought 3,000 shares on 8/8/2024Total: $24,720.00 ($8.24/share)View All Insider TransactionsView All Institutional Transactions CVRX Stock Analysis - Frequently Asked Questions How have CVRX shares performed this year? CVRx's stock was trading at $31.44 at the start of the year. Since then, CVRX stock has decreased by 75.4% and is now trading at $7.74. View the best growth stocks for 2024 here. How were CVRx's earnings last quarter? CVRx, Inc. (NASDAQ:CVRX) issued its quarterly earnings data on Monday, July, 29th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.14. The business had revenue of $11.81 million for the quarter, compared to analyst estimates of $11.84 million. CVRx had a negative trailing twelve-month return on equity of 77.62% and a negative net margin of 122.52%. When did CVRx IPO? CVRx (CVRX) raised $100 million in an initial public offering on Wednesday, June 30th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share. Who are CVRx's major shareholders? Top institutional shareholders of CVRx include Emerald Advisers LLC (2.10%), Emerald Mutual Fund Advisers Trust (1.71%), Squarepoint Ops LLC (0.43%) and Marshall Wace LLP (0.19%). Insiders that own company stock include & Johnson Johnson, Kirk G Nielsen, Joseph P Slattery, Kevin Hykes, Paul Verrastro and Mudit K Jain. View institutional ownership trends. How do I buy shares of CVRx? Shares of CVRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVRX) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CVRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CVRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVRX Stock Alerts